Zaklady Farmaceutyczne Polpharma S.A.

Zaklady Farmaceutyczne Polpharma S. A. is a prominent Polish pharmaceutical manufacturer dedicated to developing and producing a wide range of prescription and over-the-counter medications to improve health outcomes. Founded in 1935 in Starogard Gdanski, Poland, Polpharma operates as a pharmaceutical manufacturer specializing in active pharmaceutical ingredients and various dosage forms.

The company has expanded its operations over the years, establishing a significant presence in Central and Eastern Europe, the Caucasus, and Central Asia. The current leadership includes CEOs Alicja Niedzwiecka, Joanna U017bywot, and Wlodzimierz Gryglewicz, guiding the company through strategic developments in the pharmaceutical landscape. Polpharma offers an extensive portfolio of pharmaceutical products, including prescription medications and over-the-counter remedies, with a focus on active pharmaceutical ingredients. Its product range encompasses various dosage forms, such as tablets, capsules, syrups, and injectables, addressing health conditions like cardiovascular diseases, infections, and respiratory ailments.

The company serves a diverse clientele, including hospitals, pharmacies, and healthcare providers, with a strong commitment to research and development to ensure product efficacy and safety. In 2023, Polpharma reported a revenue of USD 1,058,071. 20 with an EBITDA of USD 427,560. 50.

The company generates revenue primarily through B2B sales of its pharmaceutical products to healthcare providers and pharmacies, supported by partnerships with healthcare institutions to enhance market access. Polpharma plans to introduce several new products to its portfolio, targeting innovative formulations to be launched in the upcoming years. The company is actively pursuing expansion into new markets, particularly in Central Asia and the Caucasus, by 2025. Recent funding will be allocated to enhance research and development efforts and facilitate market entry strategies, ensuring that Polpharma can effectively meet the healthcare needs of diverse patient populations.